Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis

E.N. van Roon, T.L.T.A. Jansen, M.A.F.J. van de Laar, M. Janssen, J.P. Yska, R. Keuper, P.M. Houtman, J.R.B.J. Brouwers

    Research output: Contribution to journalArticleAcademicpeer-review

    53 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)569-574
    JournalAnnals of the rheumatic diseases
    Issue number4
    Publication statusPublished - 2004

    Cite this